Extended-release niacin decreases serum fetuin-A concentrations in individuals with metabolic syndrome

被引:42
|
作者
Kaushik, Shalini V. [1 ,2 ]
Plaisance, Eric P. [2 ,3 ]
Kim, Teayoun [1 ,2 ]
Huang, Edmond Y. [1 ,2 ]
Mahurin, A. Jack [5 ]
Grandjean, Peter W. [2 ,4 ]
Mathews, Suresh T. [1 ,2 ]
机构
[1] Auburn Univ, Dept Nutr & Food Sci, Auburn, AL 36849 USA
[2] Auburn Univ, Boshell Diabet & Metab Dis Res Program, Auburn, AL 36849 USA
[3] Auburn Univ, Dept Anat Physiol & Pharmacol, Auburn, AL 36849 USA
[4] Auburn Univ, Dept Kinesiol, Auburn, AL 36849 USA
[5] Baptist Family Med Residency Program, Montgomery, AL 36116 USA
关键词
fetuin-A; niacin; Niaspan; alpha 2-HS glycoprotein; metabolic syndrome; triglycerides; MOLECULAR-WEIGHT ADIPONECTIN; RECEPTOR TYROSINE KINASE; INSULIN-RESISTANCE; NICOTINIC-ACID; INFLAMMATORY MARKERS; MEDIA THICKNESS; PLASMA; ASSOCIATION; INHIBITOR; GENE;
D O I
10.1002/dmrr.967
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Fetuin-A, a liver-secreted phosphoprotein and physiological inhibitor of insulin receptor tyrosine kinase, is associated with insulin resistance, metabolic syndrome (MetS), and an increased risk for type 2 diabetes. However, studies on the modulation of circulating levels of fetuin-A are limited. The goal of this study was to determine the effect of niacin administration on serum total- and phosphorylated fetuin-A (phosphofetuin-A) concentrations in individuals with MetS and correlate with changes in serum lipids, insulin sensitivity, and markers of inflammation. Methods Fifteen sedentary, obese, male participants, who met the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) criteria for MetS, were treated with extended-release niacin (Niaspan) for 6 weeks. Blood samples were obtained before and after treatment with niacin. Results Serum fetuin-A and phosphofetuin-A concentrations were decreased following niacin administration (p < 0.005). Changes in fetuin-A concentrations were correlated with changes in triglyceride (r = 0.62, p = 0.01) and C-reactive protein (CRP) concentrations (r = 0.58, p, < 0.05) after nacin treatment. Changes in high-density lipoproteins (HDL)-cholesterol following niacin intervention were negatively correlated with changes in serum fetuin-A (p < 0.05) and phosphofetuin-A concentrations (p < 0.05). Serum cortisol levels were significantly elevated after niacin administration. Conclusions Niacin treatment lowers serum total- and phosphofetuin-A concentrations in individuals with MetS, and these changes correlate with the beneficial changes in serum lipids. Because niacin is known to induce insulin resistance, these findings suggest that fetuin-A may not be a mediator of niacin-induced insulin resistance but it may blunt the insulin resistance induced by niacin by decreasing its circulating concentrations. Copyright (c) 2009 John Wiley & Sons, Ltd.
引用
收藏
页码:427 / 434
页数:8
相关论文
共 50 条
  • [41] Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance
    Linke, Axel
    Sonnabend, Melanie
    Fasshauer, Mathias
    Hoellriegel, Robert
    Schuler, Gerhard
    Niebauer, Josef
    Stumvoll, Michael
    Blueher, Matthias
    ATHEROSCLEROSIS, 2009, 205 (01) : 207 - 213
  • [42] Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome
    Fazio, S.
    Guyton, J. R.
    Lin, J.
    Tomassini, J. E.
    Shah, A.
    Tershakovec, A. M.
    DIABETES OBESITY & METABOLISM, 2010, 12 (11) : 983 - 993
  • [43] Plasma and urine pharmacokinetics of niacin and its metabolites from an extended-release niacin formulation
    Menon, R. M.
    Adams, M. H.
    Gonzalez, M. A.
    Tolbert, D. S.
    Leu, J. H.
    Cefali, E. A.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2007, 45 (08) : 448 - 454
  • [44] Association of fetuin-A to adiponectin ratio with metabolic syndrome: a cross-sectional study
    Ju, Huixiang
    Zhou, Zhongwei
    Sun, Mingzhong
    Chen, Hongmei
    ENDOCRINE, 2017, 58 (01) : 190 - 193
  • [45] Fetuin-A in Metabolic syndrome: A systematic review and meta-analysis
    Pan, Xiongfeng
    Wen, Shi Wu
    Bestman, Prince L.
    Kaminga, Atipatsa C.
    Acheampong, Kwabena
    Liu, Aizhong
    PLOS ONE, 2020, 15 (03):
  • [46] Flushing and other dermatologic adverse events associated with extended-release niacin therapy
    Guyton, John R.
    Simmons, Phillip D.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2009, 3 (02) : 101 - 108
  • [47] A case of acute phosphate nephropathy in a patient with nephrotic syndrome and decreased serum fetuin-A
    Han, S. H.
    Lee, J. E.
    Lee, S. H.
    Li, J. J.
    Hong, S. W.
    Han, D. S.
    Kang, S. -W.
    CLINICAL NEPHROLOGY, 2010, 74 (02) : 159 - 163
  • [48] High plasma fetuin-A levels are associated with metabolic syndrome among males but not females in a Japanese general population
    Obuchi, Aya
    Adachi, Hisashi
    Enomoto, Mika
    Fukami, Ako
    Kumagai, Eita
    Nakamura, Sachiko
    Yoshimura, Ayako
    Nohara, Yume
    Nakao, Erika
    Umeki, Yoko
    Fukumoto, Yoshihiro
    Imaizumi, Tsutomu
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 (01) : 128 - 135
  • [49] Serum fetuin-A concentrations are inversely related to cytokine concentrations in patients with chronic renal failure
    Dervisoglu, Erkan
    Kir, Hale Maral
    Kalender, Betul
    Caglayan, Cigdem
    Eraldemir, Ceyla
    CYTOKINE, 2008, 44 (03) : 323 - 327
  • [50] Level of Serum Fetuin-A Correlates with Heart Rate in Obstructive Sleep Apnea Patients without Metabolic and Cardiovascular Comorbidities
    Reichert, Elzbieta
    Mosiewicz, Jerzy
    Myslinski, Wojciech
    Jaroszynski, Andrzej
    Stanek, Agata
    Brozyna-Tkaczyk, Klaudia
    Madejska-Mosiewicz, Barbara
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2022, 19 (11)